Clinical Trial Update: Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating plasmid Elenagen in combination with gemcitabine for platinum-resistant ovarian cancer; status and results are not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Elenagen (plasmid Elenagen) (plasmid Elenagen)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: CureLab Oncology | Conditions: Ovarian Cancer, Platinum-resistant Ovarian Cancer | Phase 2 | Status: UNKNOWN